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Abstract 
Peroxisome proliferator-activated receptor-γ agonists have beneficial effects in the oxidative stress pathway by 
improving the endothelial function. Obesity, a major contributor of insulin resistance has a significant 
probability of type 2 Diabetes Mellitus, elicits oxidative stress that exacerbates the onset and progression of 
hepatotoxicity. The prospective of the research is to investigate the role of PPAR-γ agonist on insulin resistance 
and hepatocellular damages due to obesity and diabetes. 
Albino Wistar (n=40) was categorized into 5 groups; Group I: Rats fed on a normal rat diet; Group II: High fat 
diet (HFD) induced obese rats (fed on HFD for 8 weeks); Group III: HFD fed rats treated with Rosiglitazone (3 
mg/kg) for 7 days; Group IV: T2DM rats induced by HFD and low dose of Streptozotocin (i.p. 35 mg/kg); 
Group V: T2DM rats treated with Rosiglitazone (3 mg/kg) for 7 days. Insulin resistance was assessed by Serum 
insulin level and HOMA-IR. Hepatic oxidative stress was estimated by MDA, SOD, Catalase activity and 
plasma Paraoxonase -1 level. Obesity and T2DM caused a significant raised insulin resistance. There is marked 
increased MDA and decreased Catalase, SOD and plasma paraoxonase-1 activity. PPAR-γ agonist treatment 
decreased the insulin resistance in both obesity and T2DM rats and reversed and restored antioxidant status. 
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* Corresponding author.  
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 29, No  2, pp 277-289 
278 
 
The results divulge that PPAR-γ agonist not only reversed the effect of HFD and T2DM but also impede 
deleterious effects on hepatocellular damages due to insulin resistance and oxidative stress. 
Keywords: Hepatotoxicity; High fat diet; Insulin resistance; Oxidative stress; PPAR-γ agonist; Paraoxonase-1. 
1. Introduction  
Diet has been considered as the significant contributor in the etiology of obesity [1]. Obesity-related excessive 
adiposity is considered as a major contributor for several metabolic disorders, like increased systemic 
inflammation, cardiovascular risk [2], arthritis, insulin resistance [3] and especially correlate with Type 2 
Diabetes. The Pathogenic basis of Type 2 Diabetes is gradually decreased insulin action (insulin resistance) and 
unable the β-cells to restore insulin resistance that facilitate hyperglycemia and other metabolic disturbances [4]. 
Epidemiological studies linked obesity with increased production of reactive oxygen species (ROS) that cause 
endothelial dysfunction [5]. It has marked influence on β-cells, skeletal muscles and hepatocytes thus exacerbate 
insulin resistance [6, 7]. Various studies showed that oxidative stress have a critical role in the prognosis and 
pathogenesis of insulin resistance [8], which has been widely estimated in research by using the HOMA-IR 
(homeostasis model assessment-estimated insulin resistance) [9].  
There is considerable evidence that diabetes mellitus is strongly correlated with access production of free 
radicals and ultimately leads to damage oxidative stress. Another cause of increasing reactive oxygen species 
including hydrogen peroxide and superoxide dismutase is NADPH oxidase which is activated as consequences 
of increasing inflammatory cytokines [10]. Activity of serum PON1 that is an important emerging marker of 
oxidative stress is modulated both by diet and oxidative stress [11], and reported previously to be significantly 
reduced in obesity and by elevated level of oxidative stress [12]. Several evidences showed that obesity may 
leads to fatty liver which correspond to lipid accretion in the liver and exhibit increased lipid peroxidation in 
liver and a defect in anti-oxidative pathways [13]. Peroxisome proliferator-activated receptor gamma (PPAR 
gamma), is one of the important nuclear receptor. It has previously been known as an important curative and 
therapeutic target for the cure of metabolic disorders and has a potential role to combat oxidative damages 
through distinct mechanism. PPAR-γ have effective role in regulation and differentiation of adipocytes and lipid 
metabolism. Thiazolidinediones (TZDs) are PPAR- γ agonist, the class of drug that are insulin sensitizer and 
acts by activating PPAR-γ, and shown to ameliorate endothelial function of human and animals. It has a key role 
in FFA transportation and in the conversion of FFAs to triglycerides [14, 15]. However, brief researches 
available about the potential role of PPAR-γ related effects on hepatic antioxidant status in rat model of high fat 
diet induced diabetes mellitus. In this study we aimed to assess the contribution of insulin resistance, hepatic 
oxidative stress, Paraoxonase 1 activity and to identify the underlying mechanism and effects of Rosiglitazone 
in animal model of high fat diet induced obesity and type 2 diabetes mellitus. 
2. Methods 
2.1. Animals  
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Forty male Wistar rats, (180-200 g body weight), were procured from ICCBS (International Centre for Chemical 
and Biological Sciences), University of Karachi. The rats were maintained at an ambient temperature (23 ± 4°C) 
with 12-h light-dark cycles and habituated to housing conditions for 1 week before experiments. Rats had free 
access to the standard rat diet and water. Experiment was conducted according to institutional ethical guidelines. 
2.2. Preparation of High Fat Diet 
High fat diet was prepared by mixing following ingredient according to the method of Khalifa et al.2009 [16],  
7g wheat flour, 30 g of Casein, 6 g common salt, 4g bran, 10 g glucose, 3 % vitamin mixture and 40 g raw 
melted beef fat  to make palettes of 12 gram. Almost 54 % of the daily ingested calories from this diet were 
from fat contents. 
2.3. HFD/STZ Animal model of Type 2 diabetes 
HFD/STZ animal model mimicking human type 2 diabetes was designed according to Luo et al., 1998 [17], 
briefly rats were fed on High fat diet for 4 weeks and injected a single low dose of Streptozotocin (35 mg/kg) 
and continued feeding on HFD for next 4 weeks. High fat diet for 8 weeks has been used to model the Insulin 
resistance and metabolic syndrome that mimics human type 2 diabetes. Streptozotocin did not destroy all of the 
β-cells but killed some of them to renders the rats become hyperglycemic [18, 19]. Blood glucose level was 
regularly monitored. The animals having blood glucose level more than 250 mg/dl confirming type 2 Diabetes 
mellitus were included in experiment.  
2.4. Study design 
Rats were categorized into five groups (n = 8): Group I, normal control group: fed with a standard diet, Group 
II, Obese control group: fed with HFD for 8 weeks, Group III, Obese + RSG treated group: received HFD for 8 
weeks and treated with Rosiglitazone (3 mg/kg body weight) prepared in aqueous solution, daily for last 7 days 
using an intra-gastric tube, Group IV, Diabetic control group: received HFD for 8 weeks and a single i.p 
injection of Streptozotocin (35mg/kg body weight). Group V, Diabetic + RSG treated group: fed with HFD for 8 
weeks and single i.p injection of Streptozotocin (35mg/kg body weight) treated with Rosiglitazone (3 mg/kg 
body weight) in aqueous solution daily for last 7 days by an intra-gastric tube. The study design was approved 
by the Institutional Animal Ethics Committee. 
Animals from all experimental groups were weighed and their food intake with normal activity was regularly 
monitored per week. 
2.5. Sample Collection  
After 24 hours of last dose of treated groups, all the animals were decapitated by cervical dislocation blood 
samples were collected in a heparinized tube, centrifuged to collect plasma and stored at −70°C for biochemical 
analysis. Liver was excised and rinsed with ice chilled buffer saline (pH 7.0) weighed and stored at −20°C for 
further biochemical estimations. 
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2.6. Anthropometrical determinations  
Anthropometrical determination was carried out by measuring the body weight and body length of individual 
animal. 
Body mass index (BMI) was calculated as; body weight (g) / length2 (cm2)   
Lee index was estimated as; cube root of body weight (g) / nose-to-anus length (cm)  
The difference in body weight of each rat was calculated and expressed as a percentage change according to the 
following: 
%change in body weight = final body weight- initial body weigh /initial body weight ×100  [20]  
2.7. Estimation of blood glucose  
Weekly random and final fasting blood glucose levels were measured using the Glucometer (EZ II) from the tail 
vein. 
2.8. Estimation of serum insulin level 
Serum insulin conc. was estimated by using ELISA kit [21]. 
2.9. HOMA-IR determination 
HOMA-IR was used to evaluate insulin resistance (serum insulin (μU/ml) × plasma glucose (mmol/ l)/22.5) [9]. 
2.10. Assessment of Hepatic Oxidative Stress 
2.10.1. Preparation of post mitochondrial supernatant 
Liver from each rat was removed and washed with ice-chilled buffer saline. Each liver was minced, and 
homogenized with 10% (w/v) chilled 0.1 M sodium phosphate buffer, pH 7.4. The homogenate is then 
centrifuged at 1,000 rpm for 10 min at 4°C. The supernatant was used to estimate Malondialdehyde (MDA). 
10µl BHT ((butylated hydroxytoluene) (0.5M in acetonitrile) was added to the portion of homogenate for the 
assessment of Lipid peroxides to prevent the homogenate from oxidation and stored at -70ºC. To get post-
mitochondrial supernatant (PMS), homogenates was again centrifuged at 12,000 rpm for 20 min at 4°C which 
was used to assay CAT and SOD [22]. 
2.11. Estimation of Malondialdehyde (MDA) 
The Malondialdehyde (MDA) level in tissue homogenate is the measure of lipid peroxidation. The principle of 
the method is based on determination of thiobarbituric acid (TBA) reacting substance according to Okhawa et 
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al., 1979 by measuring absorbance of the pink color produced by the interaction of TBA with MDA at 530 nm 
on Schimadzu UV Spectrophotometer. Values were expressed as nmol/ml [23]. 
2.12. Estimation of Catalase 
Catalase activity in liver homogenate was assayed by the method of Sinha [24]. The activity was calculated as 
µM / g of tissue. 
2.13. Estimation of Superoxide dismutase 
Level of SOD was measured by the method of Kono, 1978 in the cell free supernatant. Percent inhibition in the 
rate of NBT reduction in the reaction mixture was recorded per minutes spectrophotometrically by Schimadzu 
UV Spectrophotometer at 560 nm [25]. 
2.14. Estimation of Plasma Paraoxonase-1 (PON1) 
Paraoxonase-1 was assayed via commercially available Kit that uses ELISA established on biotin binary 
antibody sandwich technology. (Shanghai Yehua Biological Tecnology Co.) 
2.15. Statistical analysis 
Results were expressed as mean ± S.D. Statistical analysis was carried out by SPSS program, version 10 (SPSS 
Inc, USA), values of p<0.05 were considered as statistically significant. 
3. Results 
3.1. Anthropometrical determination in Control, HFD, T2DM and treatment of PPAR-γ agonist (RSG) on 
HFD and HFD+Streptozotocin induced T2DM 
Table 1 showed the anthropometrical parameters of control, HFD fed, and T2DM groups and effect of PPAR-γ 
agonist (RSG) treatment among these groups. A Significant (p<0.05) increased % change in body weight was 
observed in animal fed on HFD for 8 weeks which reduced significantly (p<0.001) after the treatment of PPAR-
γ agonist (RSG) as compared with control. However T2DM rats showed significant (p<0.05) reduction in body 
weight when compared to both control and HFD fed obese group. Marked increased BMI was observed in HFD 
fed obese rats when compared with control (P<0.001) which decreased after RSG treatment (p<0.05). T2DM 
rats showed significant (p<0.05) increased BMI as compared with control. Treatment of T2DM with RSG 
significant (p<0.05) decreased BMI. Lee index was significantly (p<0.01) increased in HFD fed obese rays as 
compared with control. Treatment of HFD with RSG decreased lee index significantly (p<0.01) as compared 
with HFD. T2DM showed increased (p<0.05) lee index as compared with control and decreased (p<0.001) in 
HFD which decreased (p<0.001) after RSG treatment. The weights of liver were significantly (p<0.001) 
increased among all the groups as compared to control as shown in table 1. 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 29, No  2, pp 277-289 
282 
 
Table 1: Anthropometrical parameters and Organ weight in High Fat diet fed and Type 2 Diabetes mellitus rats 
with and without PPAR-γagonist (Rosiglitazone) treatment 
 
Data are presented as mean ±SD; n=8,  
***P< 0.001, **P< 0.01,*P< 0.05 with Control, ###P<0.001 
 ##P<0.01, #P< 0.05 with HFD (High Fat Diet group) 
 µµµP<0.001, µµP<0.01, µP<0.05with DM (Diabetes Mellitus group), 
P > 0.05 (Non-Significant) 
Parameters Control HFDa HFD+RSGa,b T2DMa,b, T2DM+RSGa,b,c 
Initial Body 
Weight (g)  
184.34 ± 25.52 
 
202.08 ± 25.39 208.81 ± 29.08 195.63 ± 36.98 202.75 ± 22.37 
Final Body 
Weight (g)  
201.23 ± 18.05 
 
240.25 ± 14.02 238 ± 30.91 222.75 ± 35.62 227.58 ± 29.51 
Body Weight 
Gain (g) 
16.89 ± 11.46 
 
38.17 ± 11.89 29.19 ±6.31 27.12 ± 12.70  24.83 ± 12.51 
% Change in 
body weight 
9.85 ± 7.12 
 
19.74 ± 8.02 
* 
14.16 ± 3.22 
*** 
14.80 ± 8.44 
*, # 
12.19 ± 5.82 
**, # 
Food 
Consumption 
(g) 
68.04± 6.84 
 
76.07± 6.89 75.42 ±7.24 72.90± 6.62 73.77± 5.45 
BMI (g/cm2) 0.471 ± 0.06 
 
0.604 ± 0.06 
*** 
0.512 ± 0.08 
# 
0.550 ± 0.07 
* 
0.456 ± 0.06 
# # #, µ 
Lee index (g / 
cm) 
0.351 ± 0.02 
 
0.394 ± 0.03 
** 
0.352 ± 0.02 
# # 
0.376 ± 0.02 
*, # # # 
0.333 ± 0.02 
***, µµµ 
Liver Weight (g) 5.28 ± 0.46 7.08 ± 0.511 
*** 
6.082± 0.265 
*** 
6.60 ± 0.874 
** 
6.37 ± 0.361 
***, ## 
Liver Weight 
Index(g/Kg of 
Body Weight) 
26.239 29.498 28.676 29.643 28.012 
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Table 2: Blood glucose, serum Insulin level and HOMA-IR in High Fat diet fed and Type 2 Diabetes mellitus 
rats with and without PPAR-γagonist (Rosiglitazone) treatment 
Parameters Control HFD a HFD+ RSG a, b T2DMa,b T2DM+RSGa,b,c 
BLOOD GLUCOSE 
mg/dl 
74.011 ± 2.80 89.084  ± 3.82 *** 83.038 ± 2.25 
***, ### 
472.117 ± 33.17 
***, ### 
 
276.643 ±21.04 
***, ###, µµµ 
SERUM INSULIN 
LEVEL mIU/ml 
9.028 ± 1.07 13.426 ± 1.99*** 9.954 ± 0.358 
### 
10.648 ± 3.063 9.722 ± 0.621 ### 
HOMA-IR 1.641 ± 0.22 3.006 ± 0.457*** 2.057 ± 0.074 
***, ### 
12.842 ± 4.348 
***, ### 
6.470 ± 0.686  ***, 
###, µµ 
 
Data are presented as mean ±SD; n=8,  
***P< 0.001, **P< 0.01,*P< 0.05 compared with control 
# P<0.05 compared with HFD 
µµµP<0.001, µµP<0.01 as compared with T2DM (Type 2 Diabetes mellitus) 
P>0.05(Non- Significant) 
3.2. Blood Glucose Level in Control, HFD, T2DM and treatment of PPAR-γ agonist (RSG) on HFD and 
HFD+Streptozotocin induced T2DM 
Increased level of Blood Glucose (p<0.001) were observed in HFD fed obese rats as compared to control. 
Treatment with PPAR-γ agonist (RSG) showed a significant (p<0.001) effect on Blood Glucose as compared to 
HFD fed obese rats. T2DM rats showed markedly increased Blood Glucose level (<0.001) as compared with 
control and High fat diet fed obese rats, which significantly reduced (p<0.001) by the treatment of PPAR-γ 
agonist (RSG). (Table 2) 
3.3. Serum Insulin Level and HOMA-IR in Control, HFD, T2DM and treatment of PPAR-γ agonist (RSG) 
on HFD and HFD+Streptozotocin induced T2DM 
Significantly increased serum insulin level and HOMA-IR (p<0.001) were observed in HFD fed obese rats as 
compared to control. Treatment of HFD fed rats with PPAR-γ agonist (RSG) showed a significant (p<0.001) 
decreased in serum insulin level and HOMA-IR. T2DM rats showed markedly increased HOMA-IR (<0.001) as 
compared with control and High fat diet fed obese rats, which significantly reduced (p<0.001) with the 
treatment of PPAR-γ agonist (RSG). (Table 2) 
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3.4. Hepatic Lipid Peroxidation in Control, HFD, T2DM and treatment of PPAR-γ agonist (RSG) on HFD 
and HFD+Streptozotocin induced T2DM 
Hepatic tissue MDA levels were significantly (p<0.001) increased in HFD fed rats as compared with control. 
Treatment with PPAR-γ agonist (RSG) reduced hepatic tissue MDA levels significantly (p<0.001). T2DM 
(Diabetes mellitus) rats show markedly increased in hepatic tissues MDA level (p<0. 01) as compared to HFD 
fed obese rats and decreased significantly (p<0.001) when treated with PPAR-γ agonist (RSG). 
3.5. Hepatic Catalase activity in Control, HFD, T2DM and treatment of PPAR-γ agonist (RSG) on HFD and 
HFD+Streptozotocin induced T2DM 
High fat diet fed obese rats showed nonsignificantly decreased hepatic tissues Catalase activity as compared 
with control (Figure 2). T2DM rats showed significant (p<0.01) decrease in Catalase activity as compared to 
HFD fed obese rats which markedly enhanced with the treatment of PPAR-γ agonist (p<0.01).  
3.6. Hepatic Superoxide dismutase in Control, HFD, T2DM and treatment of PPAR-γ agonist (RSG) on HFD 
and HFD+Streptozotocin induced T2DM 
SOD level in the hepatic tissues of experimental animals is depicted in Figure 3. High fat diet fed obese rats 
shows reduced level of hepatic SOD activity (p<0.05) as compared to control (Figure 3). Treatment with PPAR-
γ agonist (RSG) shows significant (p<0.001) increased in SOD activity in the Liver. T2DM showed markedly 
decreased in hepatic SOD level as compared to control (p<0.001) as well as compared to HFD fed rats (0.01). 
3.7. Serum Paraoxonase-1 activity in Liver Homogenate in Control, HFD, T2DM and treatment of PPAR-γ 
agonist (RSG) on HFD and HFD+Streptozotocin induced T2DM 
High fat diet fed obese rats shows reduced level of serum PON-1 activity (p<0.05) as compared to control 
(Figure 4).Treatment with PPAR-γ agonist (RSG) showed non significant changes in PON-1 activity.T2DM 
showed decreased PON-1 activity which increased by the treatment of PPAR-γ agonist (RSG). 
 
Figure 1: Effect of PPAR-γ agonist (RSG) treatment on hepatic Lipid peroxidation in high fat diet fed and 
Streptozotocin induced diabetic rats. 
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***P< 0.01 with Control 
 ###P<0.001, ##P<0.01, with High Fat Diet, 
µµµ P<0.001 with T2DM 
n=8, values represents the mean ±SD. 
 
Figure 2: Effect of PPAR-γ agonist (RSG) treatment on hepatic Catalase activity in high fat diet fed and 
Streptozotocin induced diabetic rats. 
**P< 0.01 with Control 
 µµP<0.01, with T2DM 
 n=8, values represents the mean ±SD. 
 
Figure 3: Effect of PPAR-γ agonist (RSG) treatment on hepatic Superoxide dismutase activity in high fat diet 
fed and Streptozotocin induced diabetic rats. 
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***P< 0.001, *P< 0.05 with Control 
 ###P<0.001, ##P<0.01 with High Fat Diet 
 n=8, values represents the mean ±SD. 
 
Figure 4:  Effect of PPAR-γ agonist (RSG) treatment on serum Paraoxonase-1 activity in high fat diet fed and 
Streptozotocin induced diabetic rats. 
*P< 0.05 with Control 
n=8, values represents the mean ±SD. 
4. Discussion 
The present study has demonstrated an animal model of obese type 2 diabetes to investigate the effects of 
PPAR-γ agonist (Rosiglitazone) treatment on the alterations in oxidative enzymes and antioxidant markers due 
to obesity and obesity induced type 2 diabetes. High fat diet or calories rich diet and less physical activity is the 
significant cause of increasing obesity and type 2 Diabetes worldwide. High fat diet cause increased 
accumulation of lipid in visceral adipose tissues. It has been previously validated that liver and adipose tissues 
in collaboration maintain the glucose and lipid homeostasis by secreting several hormone and other factors [26-
28]. Any disturbance in these tissues collaborations may cause insulin resistance and other metabolic disorders 
[29]. It has been reported that there is up-regulation of reactive oxygen species production and oxidative stress 
in liver and adipose tissue before the insulin resistance through discrete mechanism. [30]. Increase oxidation of 
free fatty acid can lead to increase reactive oxygen species production. In normal condition the antioxidant 
defense mechanism can alter these harmful changes, but in pathological condition the antioxidant defense 
system become weak and it cannot compete with the metabolic alterations hence, oxidative stress is initiated. 
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High fat diet leads to insulin resistance which is the major cause of diabetes type II. Hyperglycemia also triggers 
the oxidative stress related tissues damages which is characterized by unbalanced reactive oxygen species. 
Oxidative unbalanced in hepatic cells may cause structural damage to the hepatic tissues and may play a pivotal 
role in the genesis of the diabetic chronic liver disease. 
This study demonstrates that high fat diet and high fat diet induced Type 2 diabetes remarkably increased 
glucose level, serum insulin level, HOMA-IR, BMI (Table 1 and Table 2) and production of Lipid peroxidation  
(Figure 1) along with the reduction of antioxidant enzymes activity like Catalase (Figure2), SOD (Figure 3) in 
liver and Paraoxonase-1 activity in Plasma (Figure 4). Rosiglitazone treatment led to improved Glycemic 
control, insulin resistance and BMI in both HFD and T2DM as showed in the Table 1 and Table 2.  High fat diet 
increase the Lipid peroxidation as compare to control which decreased significantly after treatment with RSG. 
(Figure 1)  It has been reported that , Rosiglitazone, a Peroxisome proliferator-activated receptor- gamma 
agonist (PPAR-γ agonist) is an anti-diabetic drug that have imperative role in the regulation of lipid and glucose 
metabolism, inflammatory, and vascular responses as describe in previous studies [31]. It significantly 
decreased blood glucose level in type 2 diabetes and also decreased serum insulin level and hence enhanced 
insulin sensitivity as shown in Table 2. RSG has potential anti-hyperglycemic activity that attenuates the 
oxidative damages cause by hyperglycemia in hepatic tissues. CAT is ubiquitously present in a wide range in all 
types of cells where it protect against peroxidation. Due to unbalanced glucose level there is increased 
generation of reactive oxygen species in the cell that may lead to decrease Catalase activity as shown in Figure 2 
which reverse after the treatment of Rosiglitazone. While the activity of Superoxide dismutase is also decrease 
due to obesity and diabetes type II, which enhanced by the treatment of RSG as shown in Figure 3.  
The increased in PON-1 activity was suggested to have increased protection from oxidation (Figure 4). The 
treatment with Peroxisomes proliferator activated receptor gamma agonist (Rosiglitazone) alters these oxidative 
enzymes and has potentially beneficial effects that may improved insulin sensitivity and protects the hepatic 
tissue from oxidative damages. 
5. Conclusion 
The findings of the study are of merit in revealing that PPAR-γ agonist has great potential to reverse the 
oxidative stress caused by obesity and type 2 diabetes mellitus induced by high fat diet in rats. The results have 
implications in the use of PPAR-γ agonists in human for protecting against High fat diet and type II diabetes 
induced hepatotoxicity. In future studies genetic evaluation are needed to demonstrate the efficacy of the 
Rosiglitazone for the prevention and treatment of T2DM. Greater understanding of the exact mechanism of this 
pleiotropism will open the way for new therapeutics for the prevention of diabetic complications. 
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